|
1
|
Munn DH, Sharma MD, Baban B, Harding HP,
Zhang Y, Ron D and Mellor AL: GCN2 kinase in T cells mediates
proliferative arrest and anergy induction in response to
indoleamine 2,3-dioxygenase. Immunity. 22:633–642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cobbold SP, Adams E, Farquhar CA, Nolan
KF, Howie D, Lui KO, Fairchild PJ, Mellor AL, Ron D and Waldmann H:
Infectious tolerance via the consumption of essential amino acids
and mTOR signaling. Proc Natl Acad Sci USA. 106:12055–12060. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
King NJ and Thomas SR: Molecules in focus:
Indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol. 39:2167–2172.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Curti A, Trabanelli S, Salvestrini V,
Baccarani M and Lemoli RM: The role of indoleamine 2,3-dioxygenase
in the induction of immune tolerance: Focus on hematology. Blood.
113:2394–2401. 2009. View Article : Google Scholar
|
|
5
|
Alexander AM, Crawford M, Bertera S,
Rudert WA, Takikawa O, Robbins PD and Trucco M: Indoleamine
2,3-dioxygenase expression in transplanted NOD Islets prolongs
graft survival after adoptive transfer of diabetogenic splenocytes.
Diabetes. 51:356–365. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beutelspacher SC, Pillai R, Watson MP, Tan
PH, Tsang J, McClure MO, George AJ and Larkin DF: Function of
indoleamine 2,3-dioxygenase in corneal allograft rejection and
prolongation of allograft survival by over-expression. Eur J
Immunol. 36:690–700. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Tredget EE, Ghaffari A, Lin X,
Kilani RT and Ghahary A: Local expression of indoleamine
2,3-dioxygenase protects engraftment of xenogeneic skin substitute.
J Invest Dermatol. 126:128–136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seo SK, Choi JH, Kim YH, Kang WJ, Park HY,
Suh JH, Choi BK, Vinay DS and Kwon BS: 4-1BB-mediated immunotherapy
of rheumatoid arthritis. Nat Med. 10:1088–1094. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gurtner GJ, Newberry RD, Schloemann SR,
McDonald KG and Stenson WF: Inhibition of indoleamine
2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in
mice. Gastroenterology. 125:1762–1773. 2003. View Article : Google Scholar
|
|
10
|
Kwidzinski E, Bunse J, Aktas O, Richter D,
Mutlu L, Zipp F, Nitsch R and Bechmann I: Indolamine
2,3-dioxygenase is expressed in the CNS and down- regulates
autoimmune inflammation. FASEB J. 19:1347–1349. 2005.PubMed/NCBI
|
|
11
|
Munn DH, Zhou M, Attwood JT, Bondarev I,
Conway SJ, Marshall B, Brown C and Mellor AL: Prevention of
allogeneic fetal rejection by tryptophan catabolism. Science.
281:1191–1193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mellor AL, Sivakumar J, Chandler P, Smith
K, Molina H, Mao D and Munn DH: Prevention of T cell-driven
complement activation and inflammation by tryptophan catabolism
during pregnancy. Nat Immunol. 2:64–68. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Munn DH and Mellor AL: Indoleamine
2,3-dioxygenase and tumor-induced tolerance. J Clin Invest.
117:1147–1154. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eleftheriadis T, Liakopoulos V, Antoniadi
G, Stefanidis I and Galaktidou G: Indoleamine 2,3-dioxygenase is
increased in hemodialysis patients and affects immune response to
hepatitis B vaccination. Vaccine. 29:2242–2247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eleftheriadis T, Yiannaki E, Antoniadi G,
Liakopoulos V, Pissas G, Galaktidou G and Stefanidis I: Plasma
indoleamine 2,3-dioxygenase and arginase type I may contribute to
decreased blood T-cell count in hemodialysis patients. Ren Fail.
34:1118–1122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eleftheriadis T, Pissas G, Yiannaki E,
Markala D, Arampatzis S, Antoniadi G, Liakopoulos V and Stefanidis
I: Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte
reaction affects glucose influx and enzymes involved in aerobic
glycolysis and glutaminolysis in alloreactive T-cells. Hum Immunol.
74:1501–1509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eleftheriadis T, Pissas G, Karioti A,
Antoniadi G, Liakopoulos V, Dafopoulou K, Pournaras S, Koukoulis G
and Stefanidis I: The indoleamine 2,3-dioxygenase inhibitor
1-methyl-tryptophan suppresses mitochondrial function, induces
aerobic glycolysis and decreases interleukin-10 production in human
lymphocytes. Immunol Invest. 41:507–520. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang R, Dillon CP, Shi LZ, Milasta S,
Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger
J and Green DR: The transcription factor Myc controls metabolic
reprogramming upon T lymphocyte activation. Immunity. 35:871–882.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eleftheriadis T, Pissas G, Antoniadi G,
Spanoulis A, Liakopoulos V and Stefanidis I: Indoleamine
2,3-dioxygenase increases p53 levels in alloreactive human T cells
and both indoleamine 2,3-dioxygenase and p53 suppress glucose
uptake, glycolysis and proliferation. Int Immunol. 26:673–684.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guy CS, Vignali KM, Temirov J, Bettini ML,
Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai YH, Lobry C, et
al: Distinct TCR signaling pathways drive proliferation and
cytokine production in T cells. Nat Immunol. 14:262–270. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Komarov PG, Komarova EA, Kondratov RV,
Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV: A chemical
inhibitor of p53 that protects mice from the side effects of cancer
therapy. Science. 285:1733–1737. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fallarino F, Grohmann U, You S, McGrath
BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi
C, et al: The combined effects of tryptophan starvation and
tryptophan catabolites down-regulate T cell receptor zeta-chain and
induce a regulatory phenotype in naive T cells. J Immunol.
176:6752–6761. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sato T, Deiwick A, Raddatz G, Koyama K and
Schlitt HJ: Interactions of allogeneic human mononuclear cells in
the two-way mixed leucocyte culture (MLC): Influence of cell
numbers, subpopulations and cyclosporin. Clin Exp Immunol.
115:301–308. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jia L, Schweikart K, Tomaszewski J, Page
JG, Noker PE, Buhrow SA, Reid JM, Ames MM and Munn DH: Toxicology
and pharmacokinetics of 1-methyl-d-tryptophan: Absence of toxicity
due to saturating absorption. Food Chem Toxicol. 46:203–211. 2008.
View Article : Google Scholar
|
|
26
|
Jiang HY, Wek SA, McGrath BC, Scheuner D,
Kaufman RJ, Cavener DR and Wek RC: Phosphorylation of the alpha
subunit of eukaryotic initiation factor 2 is required for
activation of NF-kappaB in response to diverse cellular stresses.
Mol Cell Biol. 23:5651–5663. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sundrud MS, Koralov SB, Feuerer M, Calado
DP, Kozhaya AE, Rhule-Smith A, Lefebvre RE, Unutmaz D, Mazitschek
R, Waldner H, et al: Halofuginone inhibits TH17 cell
differentiation by activating the amino acid starvation response.
Science. 324:1334–1338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mezrich JD, Fechner JH, Zhang X, Johnson
BP, Burlingham WJ and Bradfield CA: An interaction between
kynurenine and the aryl hydrocarbon receptor can generate
regulatory T cells. J Immunol. 185:3190–3198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Opitz CA, Litzenburger UM, Sahm F, Ott M,
Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller
M, et al: An endogenous tumour-promoting ligand of the human aryl
hydrocarbon receptor. Nature. 478:197–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Elefheriadis T, Pissas G, Antoniadi G,
Spanoulis A, Liakopoulos V and Stefanidis I: Indoleamine
2,3-dioxygenase increases p53 level in alloreactive human T-cells
and both indoleamine 2,3-dioxygenase and p53 suppress glucose
uptake, glycolysis and proliferation. Int Immunol. 26:673–684.
2014. View Article : Google Scholar
|
|
31
|
Brady CA and Attardi LD: p53 at a glance.
J Cell Sci. 123(Pt 15): 2527–2532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harris SL and Levine AJ: The p53 pathway:
Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eischen CM, Weber JD, Roussel MF, Sherr CJ
and Cleveland JL: Disruption of the ARF-Mdm2-p53 tumor suppressor
pathway in Myc-induced lymphomagenesis. Genes Dev. 13:2658–2669.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Valera A, Pujol A, Gregori X, Riu E, Visa
J and Bosch F: Evidence from transgenic mice that myc regulates
hepatic glycolysis. Faseb J. 9:1067–1078. 1995.PubMed/NCBI
|
|
35
|
Shim H, Dolde C, Lewis BC, Wu CS, Dang G,
Jungmann RA, Dalla-Favera R and Dang CV: c-Myc transactivation of
LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad
Sci USA. 94:6658–6663. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Le A, Lane AN, Hamaker M, Bose S, Gouw A,
Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al:
Glucose-independent glutamine metabolism via TCA cycling for
proliferation and survival in B cells. Cell Metab. 15:110–121.
2012. View Article : Google Scholar : PubMed/NCBI
|
